- US-listed companies
- ACADIA PHARMACEUTICALS INC
- Income statement
ACADIA PHARMACEUTICALS INC (ACAD) Income statement
Market cap
$3.6B
P/E ratio
9.2x
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 2 | 5 | 1 | 0 | 0 | 17 | 125 | 224 | 339 | 442 | 484 | 517 | 726 | 958 | 1,072 |
| Revenue growth (%) | - | ||||||||||||||
| Cost of revenue | - | - | - | - | - | 3 | 9 | - | 11 | 10 | 11 | 10 | 42 | 82 | 89 |
| Research & development | 17 | 19 | 27 | 61 | 74 | 99 | 149 | 187 | 240 | 319 | 239 | 362 | 352 | 303 | 329 |
| Selling, general & administrative | - | - | - | - | - | 186 | 255 | 266 | 326 | 389 | 396 | 369 | 407 | 488 | 549 |
| Operating margin (%) | |||||||||||||||
| Operating expenses | 25 | 26 | 39 | 93 | 165 | 290 | 417 | 471 | 586 | 728 | 655 | 741 | 800 | 727 | 967 |
| Operating income | -23 | -21 | -38 | -93 | -165 | -273 | -292 | -247 | -247 | -287 | -170 | -224 | -73 | 231 | 105 |
| Income before tax | - | - | - | - | -164 | -270 | -288 | -244 | -234 | -281 | -168 | -213 | -51 | 258 | 139 |
| Pretax margin (%) | - | - | - | - | -269,037.7 | -1,558.2 | -230.8 | -109 | -69.1 | -63.6 | -34.6 | -41.3 | -7 | 26.9 | 13 |
| Provision for income taxes | - | - | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 3 | 10 | 32 | -252 |
| Effective tax rate (%) | - | - | - | - | |||||||||||
| Net income | -23 | -21 | -38 | -92 | -164 | -271 | -289 | -245 | -235 | -282 | -168 | -216 | -61 | 226 | 391 |
| Net income margin (%) | |||||||||||||||
| Earnings per share | -0.44 | -0.38 | - | - | - | - | - | - | - | - | - | -1.34 | -0.37 | 1.37 | 2.32 |
| Diluted EPS | -0.44 | -0.38 | - | - | - | - | - | - | - | - | - | -1.34 | -0.37 | 1.36 | 2.3 |